Fluorescence Imaging for Cancer Screening and Surveillance
The advent of fluorescence imaging (FI) for cancer cell detection in the field of oncology is promising for both cancer screening and surgical resection. Particularly, FI in cancer screening and surveillance is actively being evaluated in many new clinical trials with over 30 listed on Clinical Trials.gov. While surgical resection forms the foundation of many oncologic treatments, early detection is the cornerstone for improving outcomes and reducing cancer-related morbidity and mortality. The applications of FI are twofold as it can be applied to high-risk patients in addition to those undergoing active surveillance. This technology has the promise of highlighting lesions not readily detected by conventional imaging or physical examination, allowing disease detection at an earlier stage of development. Additionally, there is a persistent need for innovative, cost-effective imaging modalities to ameliorate healthcare disparities and the global burden of cancer worldwide. In this review, we outline the current utility of FI for screening and detection in a range of cancer types.
Key wordsCancer screening Early detection of cancer Neoplasms Diagnostic imaging Optical imaging Molecular imaging
We have no acknowledgements and there is no funding involved with the preparation of this manuscript.
Compliance with Ethical Standards
Conflict of Interests
The authors declare that they have no conflict of interest.
This work was supported by the National Institutes of Health (T32CA091078).
- 8.Ferlay JSI, Ervik M, Dikshit R, et al. (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013Google Scholar
- 17.American Cancer Society (2016) Cancer Facts & Figures 2016. American Cancer Society, AtlantaGoogle Scholar
- 21.National Comprehensive Cancer Network Guidelines. Head and Neck Cancers. Version 2.2013. NCCN.org. Accessed 29 Aug 2016.
- 27.Pawinski A, Sylvester R, Kurth KH et al (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urology 156:1934–1940 discussion 1940-1931CrossRefGoogle Scholar
- 32.Jichlinski P, Forrer M, Mizeret J et al (1997) Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 20:402–408CrossRefPubMedGoogle Scholar
- 40.Society AC (2015) Global cancer facts & figures, 3rd edn. American Cancer Society, AtlantaGoogle Scholar
- 73.Namikawa T, Inoue K, Shuin T, Hanazaki K (2015) Photodynamic diagnosis of gastric cancer using 5-aminolevulinic acid. In: Dip DF, Ishizawa T, Kokudo N, Rosenthal JR (eds) Fluorescence imaging for surgeons: concepts and applications. Springer International Publishing, Cham, pp 195–201CrossRefGoogle Scholar
- 79.Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) (1975-2008) SEER cancer statistics review. National Cancer Institute, BethesdaGoogle Scholar